Stoke Therapeutics, Inc. Common Stock (STOK) Stock Price

STOKStock

$33.46+65.24%52W

Market Cap$2.16B

P/E—

PEG Ratio—

Div yield—

Beta1.22

STOK Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-6.92%

Price vs S&P 500 (4W)6.92%

VGM Score32.61

P/CF (Annual)44.67x

Book Value / Share (Quarterly)$5.54

P/TBV (Annual)0.97x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)145.85%

Cash Flow / Share (Quarterly)$-2.90

Price vs S&P 500 (YTD)-10.13%

Net Profit Margin (TTM)-753.60%

EPS (TTM)$-3.36

10-Day Avg Trading Volume0.91M

EPS Excl Extra (TTM)$-3.36

EPS (Annual)$-0.12

ROI (Annual)-1.95%

Net Profit Margin (5Y Avg)-2289.09%

Cash / Share (Quarterly)$4.69

P/E Basic Excl Extra (TTM)46.10x

Revenue Growth QoQ (YoY)-32.51%

ROA (Last FY)-1.65%

Revenue Growth TTM (YoY)-86.20%

EBITD / Share (TTM)$-3.59

ROE (5Y Avg)-40.10%

Operating Margin (TTM)-809.69%

Cash Flow / Share (Annual)$0.76

P/B Ratio5.89x

P/B Ratio (Quarterly)5.90x

Net Income / Employee (Annual)$-40,500

EV / Revenue (TTM)69.82x

ROA (TTM)-51.46%

EV / EBITDA (TTM)67.01x

EPS Incl Extra (Annual)$-0.12

Current Ratio (Annual)5.28x

Quick Ratio (Quarterly)7.34x

3-Month Avg Trading Volume0.75M

52-Week Price Return65.24%

EV / Free Cash Flow (Annual)42.88x

P/E Incl Extra (TTM)46.10x

Revenue / Employee (TTM)$162,300

Tangible BV / Share (Quarterly)$3.91

P/S Ratio (Annual)11.04x

Asset Turnover (Annual)0.44x

52-Week High$40.22

Operating Margin (5Y Avg)-2353.28%

EPS Excl Extra (Annual)$-0.12

CapEx CAGR (5Y)-8.59%

26-Week Price Return4.33%

Quick Ratio (Annual)5.13x

13-Week Price Return8.93%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)7.69x

Enterprise Value$1.93B

Asset Turnover (TTM)0.07x

Book Value / Share Growth (5Y)-5.21%

Revenue / Employee (Annual)$1,084,800

Pretax Margin (Annual)-3.73%

Cash / Share (Annual)$4.83

3-Month Return Std Dev43.46%

Net Income / Employee (TTM)$-1,223,000

ROE (Last FY)-1.95%

EPS Basic Excl Extra (Annual)$-0.12

Receivables Turnover (TTM)37.67x

EV / Free Cash Flow (TTM)43.72x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.36

Receivables Turnover (Annual)34.46x

ROI (TTM)-59.36%

P/S Ratio (TTM)73.80x

Pretax Margin (5Y Avg)-2289.09%

Revenue / Share (Annual)$3.11

Tangible BV / Share (Annual)$4.69

Forward P/E3939.76x

Price vs S&P 500 (52W)46.92%

P/E Ratio (TTM)46.10x

Year-to-Date Return1.83%

5-Day Price Return0.56%

EPS Normalized (Annual)$-0.12

ROA (5Y Avg)-31.13%

Net Profit Margin (Annual)-3.73%

Month-to-Date Return11.99%

Cash Flow / Share (TTM)$-2.37

EBITD / Share (Annual)$-0.32

Operating Margin (Annual)-11.16%

P/CF (TTM)44.93x

ROI (5Y Avg)-40.10%

P/E Excl Extra (TTM)46.10x

EPS Basic Excl Extra (TTM)$-3.36

P/TBV (Quarterly)1.04x

P/B Ratio (Annual)5.14x

Pretax Margin (TTM)-758.23%

Book Value / Share (Annual)$5.98

Price vs S&P 500 (13W)6.14%

Beta1.22x

P/FCF (Annual)45.33x

Revenue / Share (TTM)$0.42

ROE (TTM)-59.36%

52-Week Low$18.00

vGradeD

gGradeF

mGradeB

vgmGradeD

STOK Earnings Surprise History

Q2 25-0.40est. -0.54

Q3 25-0.65est. -0.57

Q4 25-0.97est. -0.74

Q1 26-0.79est. -0.82

Q2 26-0.93est. -0.78

STOK Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.39

4.37

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
STOKStoke Therapeutics, Inc. Common Stock	D	F	B	$33.46
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Stoke Therapeutics, Inc. Common Stock

Stoke Therapeutics develops antisense oligonucleotides (ASOs) to treat genetic diseases through its proprietary TANGO platform, which restores protein expression in haploinsufficiency disorders. The company's lead candidate, zorevunersen, has demonstrated potential for disease modification in Dravet syndrome patients. Its pipeline focuses on mutation-agnostic treatments for rare genetic disorders affecting the central nervous system and eye.